Direct-to-consumer genome testing: Opportunities for pharmacogenomics research?

Barbara Prainsack; Howard Wolinsky

doi:10.2217/pgs.10.33

Direct-to-consumer genome testing: Opportunities for pharmacogenomics research?

Publications: Contribution to journal › Annotation › Peer Reviewed

Abstract

This commentary examines the role that commercial providers of SNP-based genome-wide personalized risk profiles play in facilitating pharmacogenomics research. We first take a look at how personal genomics services, exemplified by the company 23andMe, communicate information on drug response to customers. We then discuss the most important benefits and issues we see arising with the idea of 'crowdsourcing pharmacogenomics research via commercial genome-scan providers. We conclude with a brief vision for the future.

Original language	English
Pages (from-to)	651-655
Number of pages	5
Journal	Pharmacogenomics
Volume	11
Issue number	5
DOIs	https://doi.org/10.2217/pgs.10.33
Publication status	Published - May 2010
Externally published	Yes

Austrian Fields of Science 2012

304005 Medical biotechnology

Keywords

Crowdsourcing
Ethics
Personal genomics
Pharmacogenomics testing

Access to Document

10.2217/pgs.10.33

Cite this

@article{88c312051ce941bd9c279f5b9ca98bc4,

title = "Direct-to-consumer genome testing: Opportunities for pharmacogenomics research?",

abstract = "This commentary examines the role that commercial providers of SNP-based genome-wide personalized risk profiles play in facilitating pharmacogenomics research. We first take a look at how personal genomics services, exemplified by the company 23andMe, communicate information on drug response to customers. We then discuss the most important benefits and issues we see arising with the idea of 'crowdsourcing pharmacogenomics research via commercial genome-scan providers. We conclude with a brief vision for the future.",

keywords = "Crowdsourcing, Ethics, Personal genomics, Pharmacogenomics testing",

author = "Barbara Prainsack and Howard Wolinsky",

year = "2010",

month = may,

doi = "10.2217/pgs.10.33",

language = "English",

volume = "11",

pages = "651--655",

journal = "Pharmacogenomics",

issn = "1462-2416",

number = "5",

}

TY - JOUR

T1 - Direct-to-consumer genome testing

T2 - Opportunities for pharmacogenomics research?

AU - Prainsack, Barbara

AU - Wolinsky, Howard

PY - 2010/5

Y1 - 2010/5

N2 - This commentary examines the role that commercial providers of SNP-based genome-wide personalized risk profiles play in facilitating pharmacogenomics research. We first take a look at how personal genomics services, exemplified by the company 23andMe, communicate information on drug response to customers. We then discuss the most important benefits and issues we see arising with the idea of 'crowdsourcing pharmacogenomics research via commercial genome-scan providers. We conclude with a brief vision for the future.

AB - This commentary examines the role that commercial providers of SNP-based genome-wide personalized risk profiles play in facilitating pharmacogenomics research. We first take a look at how personal genomics services, exemplified by the company 23andMe, communicate information on drug response to customers. We then discuss the most important benefits and issues we see arising with the idea of 'crowdsourcing pharmacogenomics research via commercial genome-scan providers. We conclude with a brief vision for the future.

KW - Crowdsourcing

KW - Ethics

KW - Personal genomics

KW - Pharmacogenomics testing

UR - http://www.scopus.com/inward/record.url?scp=77951536278&partnerID=8YFLogxK

U2 - 10.2217/pgs.10.33

DO - 10.2217/pgs.10.33

M3 - Annotation

C2 - 20415555

AN - SCOPUS:77951536278

SN - 1462-2416

VL - 11

SP - 651

EP - 655

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 5

ER -

Direct-to-consumer genome testing: Opportunities for pharmacogenomics research?

Abstract

Austrian Fields of Science 2012

Keywords

Access to Document

Other files and links

Fingerprint

Cite this